IC7 Stock Chart & Stats
€123.00
-€1.00(-0.64%)
At close: 4:00 PM EST
€123.00
-€1.00(-0.64%)
Day’s Range― - ―
52-Week Range€92.00 - €136.00
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€3.25B
Enterprise Value€4.50B
Total Cash (Recent Filing)€288.33M
Total Debt (Recent Filing)€1.34B
Price to Earnings (P/E)79.3
Beta0.48
Next Earnings
Aug 10, 2026EPS Estimate
1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.87
Shares Outstanding24,993,586
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-47.74
Price to Book (P/B)1.66
Price to Sales (P/S)1.58
P/FCF Ratio38.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€145.35Price Target Upside18.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)7.05
Revenue Forecast (FY)€1.88B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueICU Medical’s core consumables business generates repeat purchasing by healthcare providers due to single-use, per-patient replacement patterns and platform standardization. This creates predictable recurring revenue, steady cash conversion and resilience to single-quarter fluctuations, supporting long-term cash flow.
Infusion Systems & Regulatory ProgressRecord pump performance and recent FDA/510(k) milestones reduce commercialization risk and expand addressable systems demand. A growing installed base of pumps increases follow-on set sales and creates platform stickiness, supporting sustained revenue and margin improvement over multiple quarters.
Improving Profitability & Cash GenerationReturn to positive net income, higher gross margin and consistent operating/free cash flow enhance financial flexibility. This supports R&D, integration spend and deleveraging plans, making the company better positioned to fund growth and absorb cyclical pressures over the medium term.
Bears Say
Revenue Shrinkage And DeconsolidationThe mid‑2025 deconsolidation materially reduced reported scale and creates comparability headwinds. Combined with ongoing negative top-line trends, smaller revenue base limits operating leverage and makes sustained margin and ROE recovery harder absent durable organic growth or inorganic scale gains.
Elevated Absolute Debt LoadA sizable absolute debt balance requires sustained free cash flow to meet deleveraging targets. Until leverage meaningfully falls, interest burden and covenant or refinancing risk can constrain strategic flexibility for R&D, M&A or share repurchase, impacting long‑term shareholder returns.
Regulatory, Tariff And Integration HeadwindsPersistent tariff/logistics sensitivity, recurring remediation/integration costs and expanded FDA testing timelines can durably pressure margins and delay new product revenue. These structural cost and timing risks raise uncertainty around margin targets and the pace at which synergies are realized.
ICU Medical News
IC7 FAQ
What was Icu Medical’s price range in the past 12 months?
Icu Medical lowest stock price was €92.00 and its highest was €136.00 in the past 12 months.
What is Icu Medical’s market cap?
Icu Medical’s market cap is €3.25B.
When is Icu Medical’s upcoming earnings report date?
Icu Medical’s upcoming earnings report date is Aug 10, 2026 which is in 41 days.
How were Icu Medical’s earnings last quarter?
Icu Medical released its earnings results on May 07, 2026. The company reported €1.699 earnings per share for the quarter, beating the consensus estimate of €1.511 by €0.188.
Is Icu Medical overvalued?
According to Wall Street analysts Icu Medical’s price is currently Undervalued.
Does Icu Medical pay dividends?
Icu Medical does not currently pay dividends.
What is Icu Medical’s EPS estimate?
Icu Medical’s EPS estimate is 1.65.
How many shares outstanding does Icu Medical have?
Icu Medical has 24,993,586 shares outstanding.
What happened to Icu Medical’s price movement after its last earnings report?
Icu Medical reported an EPS of €1.699 in its last earnings report, beating expectations of €1.511. Following the earnings report the stock price went up 1.923%.
Which hedge fund is a major shareholder of Icu Medical?
Currently, no hedge funds are holding shares in DE:IC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ICU Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€145.35 (18.17% Upside)
€145.35 (18.17% Upside)
Insider Transactions
Sold Shares
Worth €772.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.41%
12-Months-Change
Fundamentals
Return on Equity
2.19%
Trailing 12-Months
Asset Growth
-4.08%
Trailing 12-Months
Company Description
Icu Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
IC7 Company Deck
IC7 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call framed a company with healthy operational momentum in its core businesses: record Infusion Systems results, modest consumables growth, gross margin expansion, and EPS improvement (+15%). Offsetting these positives are transitory but material items that affect reported results and near-term risk: the IV Solutions deconsolidation lowering reported revenue, tariff and logistics cost pressures (potential ~$10M headwind), ongoing integration/remediation spend, and timing risk from additional FDA testing for new pump hardware. Management reiterated full-year guidance and articulated paths to offset macro and trade headwinds through tariff benefits and operational efficiencies, signaling confidence in achieving targets.View all DE:IC7 earnings summariesIC7 Stock 12 Month Forecast
Average Price Target
€145.35
▲(18.17% Upside)
Technical Analysis
Options Prices
Currently, No data available
---